Results 141 to 150 of about 5,669,348 (244)

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries. [PDF]

Ther Adv Neurol Disord
de Keijzer C, E JY, Yang Q, Gitonga R, Hiller D, Jurgensen S, Salloum N, Cunha-Santos J, Hoogewys-Cynober E, Vinet L, Chirieac M, Benzerdjeb H, Thoene D, Ziemssen T, Drahota J, Horáková D, Brown W, Hobart J, Robertson NP, Hakkarainen KM, Sinnott SJ.   +20 more
europepmc   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Nearly Optimal $L_p$ Risk Minimization

Convex risk measures play a foundational role in the area of stochastic optimization. However, in contrast to risk neutral models, their applications are still limited due to the lack of efficient solution methods.
Lan, Guanghui, Jia, Zhichao, Zhang, Zhe
core  

Blood RNA Biomarker Signatures for Early Diagnosis and Prognosis in Ischemic and Hemorrhagic Stroke: The IBIS‐CT1 Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the expression of nine blood RNA biomarkers in a clinical trial based on genes previously identified in an experimental monkey model of stroke for diagnosis feasibility and prognostication. Methods IBIS‐CT1 was a prospective longitudinal study enrolling patients with ischemic stroke (IS) or intracerebral hemorrhage (ICH ...
Salomé Retailleau, Marie Bruguet, Irina Viakhireva‐Dovganyuk, François‐Mathias Merrien, Denis Marechal, Aurore Jourdain, Philippe Goas, Jordan Coris, Julien Asselineau, Maëlys Consigny, Gérald Le Gac, Serge Timsit   +11 more
wiley   +1 more source

A Risk Minimization Approach to Messaging Intervention for Physical Activity. [PDF]

Proc Am Control Conf
Li Z, Kiani S, Lagoa CM, Conroy DE.
europepmc   +1 more source

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union. [PDF]

Drugs Real World Outcomes, 2020
Iranzo A, Serralheiro P, Schuller JC, Schlit AF, Bentz JWG.   +4 more
europepmc   +1 more source

Neurologic Manifestations of Long COVID Affect Adult Females More Severely Than Males

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize differences in neurologic manifestations of postacute sequelae of SARS‐CoV‐2 infection (Neuro‐PASC) between females and males. Methods Cross‐sectional study of the first consecutive 261 posthospitalization Neuro‐PASC (PNP) and 2068 nonhospitalized Neuro‐PASC (NNP) patients evaluated at the Neuro‐COVID clinic between ...
Hannah Kopinsky, Melissa Lopez, Janet Miller, Millenia Jimenez, Eric M. Liotta, Igor J. Koralnik   +5 more
wiley   +1 more source

Awareness of Risk Minimization Measures for Valproate and Pregnancy Prevention Program Compliance Among Pharmacists: A Cross-Sectional Survey in Romania. [PDF]

Pharmaceuticals (Basel)
Huruba M, Leucuta D, Farcas A, Mogosan C.   +3 more
europepmc   +1 more source

Deep Learning Pose Estimation for Phenotyping of Co‐Occurring Hyperkinetic Movement Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore whether routine outpatient video combined with deep learning‐based pose estimation and clinically interpretable kinematic features can support multi‐label phenotyping of co‐occurring hyperkinetic movement disorders (HMDs).
Laura Cif, Diane Demailly, Gabriella A. Horvàth, Juan Dario Ortigoza Escobar, Nathalie Dorison, Mayté Castro Jiménez, Cécile A. Hubsch, Thomas Wirth, Gun‐Marie Hariz, Sophie Huby, Morgan Dornadic, Zohra Souei, Muhammad Mushhood Ur Rehman, Simone Hemm, Mehdi Boulaymen, Eduardo M. Moraud, Jocelyne Bloch, Xavier Vasques   +17 more
wiley   +1 more source

Duration of Time Intervals for Risk Minimization Measure Effectiveness Studies. [PDF]

Clin Pharmacol Ther
Essink SCM, Zomerdijk IM, Goedecke T, Straus SMJM, Gardarsdottir H, De Bruin ML.   +5 more
europepmc   +1 more source